Silverarc Capital Management »

Relmada Therapeutics shares owned by Silverarc Capital Management

Quarter-by-quarter ownership of Relmada Therapeutics (RLMD) shares owned by Silverarc Capital Management from 13F filings

Historical chart of Silverarc Capital Management investment in Relmada Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Relmada Therapeutics held by Silverarc Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Relmada Therapeutics by Silverarc Capital Management

Quarter filed Position value Share count Share price at filing
2023-09-30 $300k 100k 3.00
2022-09-30 $15M 393k 37.02
2021-06-30 $1.5M 47k 32.01

More positions owned by Silverarc Capital Management

ImmunoGen Long Option Calls Call Option
SPRD S&P Biotech ETF Long Option Calls Call Option (XBI)
Akero Therapeutics Long Option Calls Call Option (AKRO)
Mirati Therapeutics Long Option Calls Call Option
Morphic Holding Equities (MORF)
Merus NV Equities (MRUS)
CymaBay Therapeutics Long Option Calls Call Option
Soleno Therapeutics Equities (SLNO)
Intra-Cellular Therapies Equities (ITCI)
Poseida Therapeutics Equities (PSTX)
Krystal Biotech Equities (KRYS)
Mersana Therapeutics Long Option Calls Call Option (MRSN)
KalVista Pharmaceuticals Long Option Calls Call Option (KALV)
Biogen Idec Equities (BIIB)
Urogen Pharma Equities (URGN)

View all positions for Silverarc Capital Management

Top funds holding Relmada Therapeutics

Vanguard Group
Parsons Capital Management
Opaleye Management
Palo Alto Investors
Citadel Advisors
Two Sigma Advisers
Two Sigma Investments
Point72 Asset Management
Deutsche Bank Aktiengesellschaft
Jacobs Levy Equity Management
Bank of America Corporation
Millennium Management
Guild Investment Management
Marshall Wace
Barclays

View all funds holding Relmada Therapeutics